Why Xenon Pharmaceuticals stock is down today as JPM Healthcare Conference nears
New York, January 5, 2026, 15:22 EST — Regular session Xenon Pharmaceuticals Inc (XENE) shares were down 6.5% at $41.60 in afternoon trading on Monday, about 8% off the session high. The Nasdaq-listed biotech traded between $45.21 and $41.45, with roughly 787,000 shares changing hands. The slide comes with Xenon approaching a busy stretch of investor events and trial milestones ahead of next week’s J.P. Morgan Healthcare Conference, often a tone-setter for biotech trading. Xenon’s lead molecule, azetukalner, is in Phase 3 trials — late-stage studies typically used to support drug-approval filings — in epilepsy and mood disorders, and the